To address these limitations, several monoclonal antibodies targeting AXL (such as Tilvestamab, YW327.6S2, CDX-0168, 20G7-D9, and MAb173) are being developed to enhance specificity and efficacy against cancer cells.73,114,115,146,147 Furthermore, antibody–drug conjugates (ADC) like Enapotamab Vedotin, DAXL-88, Mipasetamab Uzoptirine, and Mecbotamab Vedotin have been constructed. Here, AXL is linked to cancer.